KTTA vs KYTX

Pasithea Therapeutics Corp. vs Kyverna Therapeutics, Inc. — Valuation Comparison 2026

KTTA

Biotechnology
Pasithea Therapeutics Corp.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$0.70
Last close
Models
7/13
Active
VS

KYTX

Biotechnology
Kyverna Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
18
SAFE
Price
$8.65
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KTTA Fair ValueKTTA Upside KYTX Fair ValueKYTX Upside
Bayesian DCF Intrinsic $1.01 +45.1% $2.40 -72.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.88 +26.8% $2.70 -68.8%
Dynamic NAV Asset-Based $1.72 +147.3% $3.58 -58.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KTTA vs KYTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KTTA vs KYTX — Which Stock Is More Undervalued?

KYTX scores higher with a 4.2/10 quality rating vs KTTA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pasithea Therapeutics Corp. (KTTA) and Kyverna Therapeutics, Inc. (KYTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KTTA currently trades at $0.70 with a QOC of 4.1/10, while KYTX trades at $8.65 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).